Description:
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK)
pharmacodynamics and preliminary antitumor activity of MGC018 administered alone and in
combination with MGA012 in patients with advanced solid tumors.
Title
- Brief Title: MGC018 With or Without MGA012 in Advanced Solid Tumors
- Official Title: A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination With MGA012 (Anti-PD-1 Antibody) in Patients With Advanced Solid Tumors
Clinical Trial IDs
- ORG STUDY ID:
CP-MGC018-01
- NCT ID:
NCT03729596
Conditions
- Squamous Cell Carcinoma of Head and Neck
- Triple Negative Breast Cancer
- Melanoma
- Advanced Solid Tumor, Adult
- Metastatic Castrate Resistant Prostate Cancer
- Non Small Cell Lung Cancer
Interventions
Drug | Synonyms | Arms |
---|
MGC018 | | MGC018 Monotherapy |
MGA012 | INCMGA00012 | MGC018 plus MGA012 |
Purpose
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK)
pharmacodynamics and preliminary antitumor activity of MGC018 administered alone and in
combination with MGA012 in patients with advanced solid tumors.
Detailed Description
This Phase 1/2 study will characterize safety, dose-limiting toxicities (DLTs), and maximum
tolerated/administered dose (MTD/MAD) and anti-tumor activity for MGC018 as monotherapy
(Module A) in patients with advanced solid tumors. Each module consists of a Dose Escalation
(3+3+3 design) followed by a Cohort Expansion Phase. Patients with solid tumors will be
enrolled in the Dose Escalation Phase; Cohort Expansion will include metastatic
castrate-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC),
triple-negative breast cancer (TNBC), squamous cell carcinoma of the head and neck (SCCHN),
and melanoma. Patients who do not experience unacceptable toxicity or meet criteria for
permanent discontinuation may undergo additional cycles for up to two years. Patients in
Cohort Expansion will be followed for survival every 3 months for 2 years following last
dose.
Module B, MGC018 in combination with MGA012, Dose Escalation and Cohort Expansion will
commence only upon sponsor notification to all study investigators.
Trial Arms
Name | Type | Description | Interventions |
---|
MGC018 Monotherapy | Experimental | MGC018: Anti-B7-H3 antibody drug conjugate | |
MGC018 plus MGA012 | Experimental | MGC018: Anti-B7-H3 antibody drug conjugate; MGA012: Anti-PD-1 antibody | |
Eligibility Criteria
Inclusion Criteria:
- Tissue specimen available for retrospective analysis of B7-H3 and PD-L1 expression.
- Eastern Cooperative Oncology Group performance status of ≤2
- Life expectancy ≥ 12 weeks for dose escalation phase and ≥ 24 weeks for cohort
expansion phase
- Measurable disease. Prostate cancer patients with bone only disease are eligible.
- Acceptable laboratory parameters and adequate organ reserve.
- Dose Escalation Phase: Patients with histologically proven, unresectable, locally
advanced or metastatic solid tumors for whom no therapy with demonstrated clinical
benefit is available.
Module A Cohort Expansion:
- mCRPC that has progressed with one prior line of chemotherapy for metastatic disease
and no more than two prior lines of anti-hormonal therapy.
- NSCLC: metastatic disease after standard cytotoxic, targeted, and biologic or
checkpoint inhibitor therapy. No more than 2 prior lines of chemotherapy.
- TNBC: Locally advance or metastatic disease that has progressed following at least one
systemic therapy.
- SCCHN that has progressed during or following at least one systemic therapy for
metastatic or recurrent unresectable disease. No more than 2 prior lines of
chemotherapy.
- Melanoma that has progressed during or following at least one systemic treatment for
unresectable locally advanced or metastatic disease. Patients who are intolerant of or
refused standard therapy are eligible.
Exclusion Criteria:
- Patients with history of prior central nervous system (CNS) metastasis must have been
treated, be asymptomatic, and not have concurrent treatment for CNS disease,
progression of CNS metastases on MRI, CT or PET within 6 months, or history of
leptomeningeal disease or cord compression at the time of enrollment.
- Prior treatment with B7-H3 targeted agents for cancer.
- Treatment with systemic cancer therapy, biologic agents, or anti-hormonal therapy
(mCRPC) within 4 weeks, prior small molecule targeted or kinase inhibitors within 14
days or 5 half-lives, prior radioligand within 6 months
- Clinically significant cardiovascular disease.
- Clinically significant pulmonary compromise or requirement for supplemental oxygen.
- History of clinically-significant cardiovascular disease, including but not limited to
pericarditis or pericardial effusion.
- Active viral (including confirmed or presumed COVID-19), bacterial, or systemic fungal
infection requiring parenteral treatment within 7 days of first study drug
administration.
- Known history of hepatitis B or C infection or known positive test for hepatitis B
surface antigen or core antigen, or hepatitis C polymerase chain reaction.
- Known positive testing for human immunodeficiency virus or history of acquired immune
deficiency syndrome.
- Major trauma or major surgery within 4 weeks of first study drug administration.
- Clinically significant venous insufficiency.
- > Grade 1 peripheral neuropathy.
- Evidence of pleural effusion.
- Evidence of ascites.
- Serum testosterone >50 ng/dl or >1.7 nmol/L in mCRPC in Module A Cohort Expansion
Phase
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Incidence of Adverse Events of MGC018 and MGC018 + MGA012 as assessed by CTCAE v4.03 |
Time Frame: | 30 days after last dose |
Safety Issue: | |
Description: | Safety is based on evaluation of adverse events (AEs) and serious adverse events (SAEs) from the time of study drug administration through the End of Study visit. |
Secondary Outcome Measures
Measure: | Preliminary anti-tumor activity of MGC018 and MGC018+MGA012 |
Time Frame: | 24 months |
Safety Issue: | |
Description: | Efficacy assessed as best overall response rate using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) |
Measure: | PSA response rate |
Time Frame: | 24 months |
Safety Issue: | |
Description: | Percent of prostate cancer patients with at least 50% reduction in prostate-specific antigen (PSA) |
Measure: | Best PSA response |
Time Frame: | 24 months |
Safety Issue: | |
Description: | The greatest change from baseline in PSA. |
Measure: | Radiographic progression-free survival |
Time Frame: | 24 months |
Safety Issue: | |
Description: | For prostate cancer patients, time from first dose to first radiographic progression in soft tissue or bone, or death from any cause |
Measure: | Patient-reported Outcome |
Time Frame: | 24 months |
Safety Issue: | |
Description: | For prostate cancer patients, change from baseline in pain intensity as measured by the Brief Pain Inventory-Short Form scale |
Measure: | Area under the curve |
Time Frame: | 24 months |
Safety Issue: | |
Description: | Area under the plasma concentration versus time curve of MGC018 and MGC018+MGA012 |
Measure: | Cmax |
Time Frame: | 24 months |
Safety Issue: | |
Description: | Maximum Plasma Concentration of MGC018 and MGC018+MGA012 |
Measure: | Tmax |
Time Frame: | 24 months |
Safety Issue: | |
Description: | Time to reach maximum (peak) plasma concentration of MGC018 and MGC018+MGA012 |
Measure: | Ctrough |
Time Frame: | 24 months |
Safety Issue: | |
Description: | Trough plasma concentration of MGC018 and MGC018+MGA012 |
Measure: | CL |
Time Frame: | 24 months |
Safety Issue: | |
Description: | Total body clearance of the drug from plasma of MGC018 and MGC018+MGA012 |
Measure: | Vss |
Time Frame: | 24 months |
Safety Issue: | |
Description: | Apparent volume of distribution at steady state of MGC018 and MGC018+MGA012 |
Measure: | t1/2 |
Time Frame: | 24 months |
Safety Issue: | |
Description: | Terminal half life of MGC018 and MGC018+MGA012 |
Measure: | Immunogenicity |
Time Frame: | 24 months |
Safety Issue: | |
Description: | Percent of patients with anti-drug antibodies against MGC018 and MGA012 |
Details
Phase: | Phase 1/Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | MacroGenics |
Trial Keywords
- antibody-drug conjugate (ADC)
- B7-H3
Last Updated
August 23, 2021